Stocks Health care BLRX

NASDAQ · Health care

BioLineRx Ltd. (BLRX)

BioLineRx Ltd. reported revenue of $1.2M in fiscal 2025, down 95.9% from a year earlier. It posted a net loss of $2M. In fiscal 2025 capital spending exceeded operating cash flow by $8.1M. At December 31, 2025 it held $3.3M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer, amended) (20-F/A) filed on March 27, 2026.

Watch BLRX in 60 seconds

Follow BLRX

Free, no password. An email when BLRX files with the SEC.

Key facts about BioLineRx Ltd.

Net worth

BioLineRx Ltd. has a market value (market cap) of $6.6M at the latest share price, and shareholders' equity of $18.2M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2025 revenue was $1.2M (-95.9% year on year), with a net loss of $2M.

Cash flow

In fiscal 2025 operations used $8.1M of cash.

Latest report

The latest periodic report (annual report (foreign issuer, amended), 20-F/A) was filed with the SEC on March 27, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR

What BioLineRx Ltd. does

BioLineRx Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BLRX.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where BLRX ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What BioLineRx Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 25, 2026
   IPO registration (foreign issuer) F-1
2. September 24, 2026
   Foreign issuer update 6-K
3. September 10, 2026
   Foreign issuer update 6-K
4. August 31, 2026
   Foreign issuer update 6-K
5. August 31, 2026
   Foreign issuer update 6-K
6. August 28, 2026
   Foreign issuer update 6-K
7. August 18, 2026
   Foreign issuer update 6-K
8. July 8, 2026
   Foreign issuer update 6-K
9. May 27, 2026
   Foreign issuer update 6-K
10. May 22, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on April 10, 2026. Insider transactions on SEC

Insider trades

What the people running BioLineRx Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns BLRX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Mitchell P. Kopin 4.99% (January 10, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BLRX

What does BioLineRx Ltd. do?

BioLineRx Ltd. is a company in the Health care sector, listed on NASDAQ as BLRX. Its shares trade on NASDAQ under the ticker BLRX.

What is BioLineRx Ltd.'s net worth?

BioLineRx Ltd. has a market value (market cap) of $6.6M at the latest share price, and shareholders' equity of $18.2M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is BioLineRx Ltd. profitable?

No. In fiscal 2025 it reported a net loss of $2M on revenue of $1.2M.

How much revenue does BioLineRx Ltd. make?

In fiscal 2025 BioLineRx Ltd. reported revenue of $1.2M. That is 95.9% less than a year earlier.

When did BioLineRx Ltd. last report?

Its most recent periodic report is the annual report (foreign issuer, amended) (20-F/A) filed on March 27, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the iPO registration (foreign issuer) from September 25, 2026.

Similar companies

Compare BLRX with

Compare BLRX with any company

Follow BLRX

Get an email when BioLineRx Ltd. files with the SEC: results, executive changes, material agreements and annual reports.

Follow BLRX

Free, no password. An email when BLRX files with the SEC.

Where the numbers come from

Financial figures are the values BioLineRx Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.